Ever Supreme Bio Technology

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine (ADCV01), a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; chimeric antigen receptor immune cells (CAR001), a chimeric antigen receptor immune cells product; and allogeneic bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. In addition, the company develops allogeneic umbilical cord mesenchymal stem cells (UMSC01), used to treat cardiovascular diseases and strokes. Further, it engages in the sale of other health products and related businesses; and cell preparations and investment activities in biotechnology and medical industry businesses. The company was incorporated in 2016 and is based in Taichung, Taiwan.